Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND).

Autor:	Sehn, L. H., Kuruvilla, J., Salles, G., Maddocks, K. J., Koch, C., Xue, Z., Amoloja, T., Amin, A., Duell, J.
Předmět:	DIFFUSE large B-cell lymphomas LENALIDOMIDE ANTIBODY-dependent cell cytotoxicity STOCK ownership
Zdroj:	Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p441-442, 2p
Abstrakt:	Results of this post hoc internal control analysis support potential benefit of tafa/len as a 2L treatment option for ASCT-ineligible pts with R/R DLBCL, as demonstrated in L-MIND. Using the L-MIND 35-month follow-up data (October 30, 2020 data cutoff), the IN 2L-MIND post hoc analysis assessed 2L clinical outcomes in pts evaluated in 2 cohorts: pts treated with tafa/len as 2L therapy during the study (tafa/len cohort) and pts who received 2L systemic therapy prior to entering L-MIND (SOC cohort). B Conclusions: b From the IN 2L-MIND analysis, pts receiving tafa/len as 2L therapy in L-MIND had longer PFS than pts who received 2L SOC prior to study enrollment. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text